In an accompanying Comment, Dr Luigi Gennari, University of Siena, Italy, and Professor John P Bilezikian, Columbia University, New York, USA, say: "Although a once-yearly intravenous infusion of ...

Please provide your email address to receive an email when new articles are posted on . A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral ...

GLASGOW, Scotland – A single infusion of zoledronic acid (Aclasta) prevents bone turnover in people at risk of Paget’s disease in an analysis of data from the Zoledronate in the Prevention of Paget’s ...

Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group. In Spain, adherence to the recommended dose of ZA was suboptimal. Most ...

In general, IV bisphosphonates are very well tolerated, and patients rarely require dose modification. In the comparative phase 3 trial of zoledronic acid and pamidronate in patients with breast ...

Financial and psychosocial impacts of adjuvant chemotherapy in older colorectal cancer patients. Background: Acute renal failure (ARF) is an adverse event associated with the use of zoledronic acid, ...

Yearly infusion of zoledronic acid is as good as, and possibly even better than, daily oral risedronate for prevention and treatment of bone loss as a result of glucocorticoid therapy, according to ...

Please provide your email address to receive an email when new articles are posted on . “Discontinuation of denosumab results in high-turnover bone loss and increased fracture risk,” Sabashini ...